MAYNE PHARMA GROUP LIMITED (MYX)
Share Price Analysis and Chart

Enter the company code or Name for stock analysis:

MYX - MAYNE PHARMA GROUP LIMITED

FNArena Sector : Pharmaceuticals & Biotech/Lifesciences
Year End: June
GICS Industry Group : Pharmaceuticals, Biotechnology & Life Sciences
Index: ASX300 | ALL-ORDS

LAST PRICE CHANGE +/- CHANGE % VOLUME

$0.30

25 May
2022

0.000

OPEN

$0.29

0.000

HIGH

$0.30

2,271,550

LOW

$0.29

TARGET
$0.26 -13.3% downside
Franking for last dividend paid out: 0%
OTHER COMPANIES IN THE SAME SECTOR
CUV . ACR . AHZ . CSL . IDT . IVX . MSB . RNO . OSL . TFC . TIS . KZA . AGH . FTT . PAR . ADO . PYC . RAC . RCE . ZNO . AVH . LGP . SPL . ARX . AFP . 1AD . TLX . PNV . MVP . BNO . NXS . GSS . EOF . NEU . PAL . PBP . BOT . IMU . MDC . IMM . PXS . HXL . MXC . OPT . ANP .
FNARENA'S MARKET CONSENSUS FORECASTS
MYX: 1
Title FY20
Actual		 FY21
Actual		 FY22
Forecast		 FY23
Forecast
EPS (cps) xxx - 13.3 - 2.5 xxx
DPS (cps) xxx 0.0 0.0 xxx
EPS Growth xxx N/A N/A xxx
DPS Growth xxx N/A N/A xxx
PE Ratio xxx N/A N/A xxx
Dividend Yield xxx N/A 0.0% xxx
Div Pay Ratio(%) xxx N/A N/A xxx

Dividend yield today if purchased 3 years ago: 0.00%

DIVIDEND YIELD CALCULATOR

Dividend Yield Today On Last Actual Payout :

 0.00

Estimated Dividend Growth
(Average Of Past Three Years)

  %

Amount Invested

 $ 

Tell Me The Dividend After This Many Years
Past performance is no guarantee for the future. Investors should take into account that heavy swings in share price or exceptional circumstances (a la 2009) can have a significant impact on short term calculations and averages
HISTORICAL DATA ARE ALL IN AUD
Copyright © 2022 FactSet UK Limited. All rights reserved
Title 201620172018201920202021
EPS Basic xxxxxxxxxxxxxxx-13.3
DPS All xxxxxxxxxxxxxxx0.0
Sales/Revenue xxxxxxxxxxxxxxx400.8 M
Book Value Per Share xxxxxxxxxxxxxxx43.5
Net Operating Cash Flow xxxxxxxxxxxxxxx47.3 M
Net Profit Margin xxxxxxxxxxxxxxx-52.00 %

EPS Basic

DPS All

Sales/Revenue

Book Value Per Share

Net Operating Cash Flow

Net Profit Margin

Title 201620172018201920202021
Return on Capital Employed xxxxxxxxxxxxxxx-23.08 %
Return on Invested Capital xxxxxxxxxxxxxxx-17.00 %
Return on Assets xxxxxxxxxxxxxxx-12.55 %
Return on Equity xxxxxxxxxxxxxxx-23.08 %
Return on Total Capital xxxxxxxxxxxxxxx0.11 %
Free Cash Flow ex dividends xxxxxxxxxxxxxxx30.2 M

Return on Capital Employed

Return on Invested Capital

Return on Assets

Return on Equity

Return on Total Capital

Free Cash Flow ex dividends

This is work in progress. Bear with us. It'll be amazing.

EXPERT VIEWS
Display All Commentary

Sentiment Indicator

0.0

No. Of Recommendations

2
BROKER DATE RATING RECOMMENDATION TARGET PRICE % TO REACH TARGET COMMENTARY

Citi

xx/xx/xxxx

3

xxxxxxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial

Credit Suisse

28/02/2022

3

Neutral

$0.27

-10.00%

Mayne Pharma Group's December first-half result met consensus forecasts, and excludes the -$32m decline in the fair value of earn-out of Nextellis, says Credit Suisse.

Price erosion continued to hit the generic retail business, revenue slumping -29% and profit down -50%. Gross cash conversion was soft and the broker notes net debt/EBITDA has fallen below covenant.

The broker forecasts a return to earnings growth in the second half, thanks largely to Dermatology as more products hit the market.

Netural rating retained, the broker awaiting a strong ramp-up in Nextstellis. Target price falls to 27c from 30c.

FORECAST
Credit Suisse forecasts a full year FY22 dividend of 0.00 cents and EPS of minus -2.54 cents.
Credit Suisse forecasts a full year FY23 dividend of 0.00 cents and EPS of 0.26 cents.
Access Stockbroker Research History >

MYX STOCK CHART

FNArena News on MYX

1
Australian Broker Call *Extra* Edition – Apr 07, 2022

Apr 07 2022 - Daily Market Reports
2
FNArena Corporate Results Monitor – 28-02-2022

Feb 28 2022 - Australia
3
Rudi’s View: February Results; Macro, Traps And Opportunities

Feb 10 2022 - Rudi's View
4
Australian Broker Call *Extra* Edition – Nov 26, 2021

Nov 26 2021 - Daily Market Reports
5
Australian Broker Call *Extra* Edition – Sep 30, 2021

Sep 30 2021 - Daily Market Reports

Latest Pharmaceuticals & Biotech/Lifesciences News

1
CSL: Buy Trigger Ahead

Apr 26 2022 - Technicals
2
Why CSL Fell Sharply Yesterday

Dec 17 2021 - Australia
3
Beating The Biotech Blues

Sep 14 2021 - International
4
Uncertainty Prevails For CSL

Aug 19 2021 - Australia
5
Flying High – Medicinal Marijuana In Australia

Jul 26 2021 - Australia
6
Wesfarmers On Drugs?

Jul 13 2021 - Australia
7
Is CSL’s Plasma Recovery Now Priced In?

Jun 23 2021 - Australia
8
CSL: Buy The Dip

Jun 22 2021 - Technicals
9
CSL To Retest Its High?

May 25 2021 - Technicals
10
Treasure Chest: CSL Plasma At Turning Point?

May 05 2021 - Treasure Chest